BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $149.45M rose 34.4% year over year, ahead of the +12.1% change in trailing-twelve-month research & development. Sequentially, it rose 18.0% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Research & development amounted to 95.1% of revenue in FY2025, down 133.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +34.4% holds above the trailing-twelve-month pace of +12.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 477.54M USD
- Year-over-year change
- -5.7%
- 4-year CAGR
- +1.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 477.54M | -5.7% |
| FY2024 | 2024-12-31 | 506.46M | +11.1% |
| FY2023 | 2023-12-31 | 455.71M | +14.1% |
| FY2022 | 2022-12-31 | 399.46M | -11.4% |
| FY2021 | 2021-12-31 | 451.02M | — |
Research & Development vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.1% is the 6th highest of 11, against a peer median of +8.6%.
- Research & development amounts to 74.5% of revenue for BBIO, versus a peer median of 69.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B USD | +19955.1% | +12.4% | 17.6% | |
| LTM Jun 2026 | $1.51B USD | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M USD | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $770.95M USD | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $530.96M USD | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $433.31M USD | -14.7% | -11.3% | 43.0% | |
| LTM Jun 2026 | $400.72M USD | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | €274.3M EUR | -10.0% | -9.3% | 22.7% | |
| LTM Sep 2026 | $245.55M USD | +16.8% | -3.2% | 37.7% | |
| LTM Sep 2026 | $211.05M USD | -0.0% | +18.8% | 37026.5% | |
| LTM Mar 2026 | $114.57M USD | +28.4% | +7.1% | 572.9% | |
| Peer median (excluding BBIO) | — | +8.6% | +4.3% | 69.6% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.